Oculis Holding AG (NASDAQ:OCS - Get Free Report) shares reached a new 52-week high during trading on Monday . The stock traded as high as $16.87 and last traded at $16.09, with a volume of 4021 shares. The stock had previously closed at $15.80.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reiterated a "buy" rating and set a $30.00 price target on shares of Oculis in a research report on Wednesday, October 23rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $29.20.
Read Our Latest Research Report on Oculis
Oculis Price Performance
The company has a market capitalization of $690.59 million, a PE ratio of -9.52 and a beta of 0.30. The company has a current ratio of 5.27, a quick ratio of 5.27 and a debt-to-equity ratio of 0.01. The stock's 50-day moving average is $12.97 and its two-hundred day moving average is $12.25.
Oculis (NASDAQ:OCS - Get Free Report) last released its earnings results on Tuesday, August 27th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.13). The company had revenue of $0.27 million for the quarter, compared to analysts' expectations of $0.28 million. Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. On average, equities analysts predict that Oculis Holding AG will post -2.19 EPS for the current year.
About Oculis
(
Get Free Report)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
See Also
Before you consider Oculis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oculis wasn't on the list.
While Oculis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
